‘Guided Missile Drugs’ Could Be Big Pharma’s Secret Weapon
Merck and Pfizer are the latest big pharma companies to invest in this booming area.
Monday, June 1, 2026
Tag: Biology
Biogen’s New Boss Is Delivering, but Stock Isn’t Pricing It in Yet
The decision to buy Reata signals a new era under CEO Chris Viehbacher, and Wall Street’s skepticism presents an opportunity.
Biotech Stocks Join AI-Fueled Rally
Shares of Recursion Pharmaceuticals, Schrodinger and others that are implementing AI are surging.
As Washington Clamps Down on Big Pharma, Small Is Beautiful Again
Large drug companies need innovation to deal with the drug-pricing law. That is a boon to smaller biotech firms.
WSJ News Exclusive | Farallon Capital to Wage Proxy Battle at Biotech Firm
WSJ News ExclusiveFinanceFarallon has nominated three directors to the board of Exelixis
World’s Top-Selling Drug Going Off Patent Means Big Bucks for Middlemen
MarketsHeard on the StreetAs AbbVie’s Humira faces copycat biologics, the biggest beneficiaries will be the middlemen negotiating and dispensing the ...
EDITOR'S PICK
EP NEWSROOM
© 2025 Edinburg Post or its affiliated companies.